Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423
Recruiting
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Ovarian Cancer, Solid Tumor
Register for Updates
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571
Recruiting
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut
Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT05671991
Recruiting
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Yale University, New Haven, Connecticut
Conditions: End Stage Renal Disease on Dialysis
Register for Updates
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Recruiting
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
02/27/2025
Locations: Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05234567
Recruiting
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Clinical Trial Site, Hartford, Connecticut
Conditions: Hypophosphatasia
Register for Updates
Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
NCT05207085
Recruiting
This trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the treatment of trichotillomania (TTM) in a double blind placebo controlled design study. After week 12, subjects will begin a 12-week, open-label portion of the study. During the open-label portion of the study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies wil... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/26/2025
Locations: Yale Child Study Center, New Haven, Connecticut
Conditions: Trichotillomania (Hair-Pulling Disorder)
Register for Updates
Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture
NCT05883241
Recruiting
The purpose of this study is to assess the ability of long-duration low-intensity therapeutic ultrasound (LITUS) to alleviate bone-fracture related pain over a 12-week period. The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from bone-fracture pain. Secondary objectives are to assess the ability of LITUS to improve patients return to work time.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/25/2025
Locations: ZetrOZ Systems LLC, Trumbull, Connecticut
Conditions: Bone Fracture, Fresh Fracture
Register for Updates
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
NCT06652100
Recruiting
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/24/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Kidney Injury
Register for Updates
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331
Recruiting
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/24/2025
Locations: Yale University / Yale New Haven Hospital, New Haven, Connecticut
Conditions: In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Register for Updates
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
NCT05309616
Recruiting
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Idiopathic Subglottic Stenosis
Register for Updates
Dermal Allograft Augmentation of Large and Massive Rotator Cuff Tears
NCT05981833
Recruiting
The purpose of this study is to compare postoperative healing of large and massive rotator cuff tears with preoperative MRI confirmed fatty infiltration stage II and higher repaired with or without dermal allograft augmentation (DAA).
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
02/21/2025
Locations: Orthopaedic & Nuerosurgery Specialists, Greenwich, Connecticut
Conditions: Full-thickness Rotator Cuff Tear
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Farmington, Connecticut
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates